- Home
- AQST vs BRW Comparison
AQST vs BRW Comparison
Compare AQST & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- BRW
- Stock Information
- Founded
- AQST 2004
- BRW 1987
- Country
- AQST United States
- BRW United States
- Employees
- AQST 135
- BRW N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- AQST Health Care
- BRW Finance
- Exchange
- AQST Nasdaq
- BRW Nasdaq
- Market Cap
- AQST 274.4M
- BRW 332.9M
- IPO Year
- AQST 2018
- BRW N/A
- Fundamental
- Price
- AQST $3.01
- BRW $7.88
- Analyst Decision
- AQST Strong Buy
- BRW
- Analyst Count
- AQST 8
- BRW 0
- Target Price
- AQST $10.38
- BRW N/A
- AVG Volume (30 Days)
- AQST 2.0M
- BRW 222.1K
- Earning Date
- AQST 03-05-2025
- BRW 01-01-0001
- Dividend Yield
- AQST N/A
- BRW 15.59%
- EPS Growth
- AQST N/A
- BRW N/A
- EPS
- AQST N/A
- BRW N/A
- Revenue
- AQST $58,900,000.00
- BRW N/A
- Revenue This Year
- AQST $18.44
- BRW N/A
- Revenue Next Year
- AQST N/A
- BRW N/A
- P/E Ratio
- AQST N/A
- BRW N/A
- Revenue Growth
- AQST 22.56
- BRW N/A
- 52 Week Low
- AQST $2.24
- BRW $7.15
- 52 Week High
- AQST $6.23
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- AQST 43.29
- BRW 55.70
- Support Level
- AQST $2.95
- BRW $7.83
- Resistance Level
- AQST $3.21
- BRW $7.88
- Average True Range (ATR)
- AQST 0.20
- BRW 0.08
- MACD
- AQST 0.02
- BRW 0.00
- Stochastic Oscillator
- AQST 18.42
- BRW 63.16
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.